22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
CEO: Lawrence D. Firestone. Company website
22nd Century Group, Inc. (XXII) trades at $1.79, up 1.13% on the day, as of Sep 20, 2026 13:44 UTC.
22nd Century Group, Inc. has a market capitalisation of $617,771.96, calculated from the live XXII share price and shares outstanding.
XXII has no meaningful price-to-earnings ratio: 22nd Century Group, Inc. lost $131.00 per share over the last twelve months, and a P/E is only defined on positive earnings.
22nd Century Group, Inc. generated revenue of $9.52M over the trailing twelve months, which puts the stock at 0.06 times sales.
XXII has traded between $1.67 and $646.50 over the past 52 weeks, and the last price is 99.7% below that high.
No. 22nd Century Group, Inc. is loss-making, with a net margin of -41.26% over the trailing twelve months.
Wall Street analysts rate XXII Buy, with an average price target of $1,237.50, 69,034.1% above the current price.
22nd Century Group, Inc. is classified under the Consumer Defensive sector and the Tobacco industry, and is domiciled in US.
Lawrence D. Firestone is the chief executive of 22nd Century Group, Inc., which employs 32 people.
QFI Terminal shows XXII with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open XXII in Terminal See plans